Quick Answer
Design Therapeutics, Inc. reported Total Revenue of $226.0 thousand for fiscal year 2020.
Design Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | $226.0K |
| Revenue (ASC 606) | — | — | — | — | — | $226.0K |
| Net Income | -$69.79M -40.7% |
-$49.59M +25.8% |
-$66.86M -5.6% |
-$63.31M -78.2% |
-$35.53M -329.1% |
-$8.28M |
| Diluted EPS | -$1.22 -38.6% |
-$0.88 +26.1% |
-$1.19 -4.4% |
-$1.14 -48.1% |
-$0.77 | — |
| Total Assets | $226.20M -10.3% |
$252.09M -13.0% |
$289.64M -15.1% |
$341.14M -12.7% |
$390.56M +969.6% |
$36.52M |
| Cash and Equivalents | $16.86M -25.3% |
$22.56M +6.4% |
$21.20M -20.0% |
$26.50M -91.1% |
$298.57M +12450.2% |
$2.38M |
| Stockholders Equity | $212.50M -12.2% |
$242.10M -12.8% |
$277.69M -15.2% |
$327.31M -14.3% |
$382.13M +3477.2% |
-$11.31M -210.7% |
| R&D Expense | $59.13M +33.3% |
$44.35M -22.3% |
$57.06M +17.4% |
$48.61M +96.2% |
$24.78M +308.9% |
$6.06M |
| Operating Income | -$79.47M -27.4% |
-$62.38M +20.2% |
-$78.19M -15.7% |
-$67.59M -88.6% |
-$35.83M -330.1% |
-$8.33M |
| Shares Outstanding | 60.40M +6.4% |
56.75M +0.5% |
56.47M +1.0% |
55.90M +0.8% |
55.44M +247.4% |
15.96M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2020 | $20.0K | — | -35.5% |
| Revenue (ASC 606) | September 30, 2020 | $20.0K | — | -35.5% |
| Net Income | September 30, 2025 | -$17.00M | -30.4% | +10.9% |
| Diluted EPS | September 30, 2025 | -$0.30 | -30.4% | +11.8% |
| Total Assets | September 30, 2025 | $211.77M | -19.1% | -5.0% |
| Cash and Equivalents | September 30, 2025 | $15.09M | -50.3% | -23.4% |
| Stockholders Equity | September 30, 2025 | $199.72M | -20.9% | -6.3% |
| R&D Expense | September 30, 2025 | $14.59M | +22.8% | -7.3% |
| Operating Income | September 30, 2025 | -$19.31M | -18.9% | +10.5% |
| Shares Outstanding | September 30, 2025 | 56.96M | +0.6% | +0.0% |
- Design Therapeutics, Inc. reported Total Revenue of $226.0 thousand for fiscal year 2020.
- Design Therapeutics, Inc. reported Revenue (ASC 606) of $226.0 thousand for fiscal year 2020.
- Design Therapeutics, Inc. reported Net Income of -$69.79 million for fiscal year 2025.
- Design Therapeutics, Inc. showed a decrease of -40.7% in Net Income compared to the prior fiscal year.
- Design Therapeutics, Inc. reported Diluted EPS of $1.22 per share (loss) for fiscal year 2025.
- Design Therapeutics, Inc. showed a decrease of -38.6% in Diluted EPS compared to the prior fiscal year.
- Design Therapeutics, Inc. reported Total Assets of $226.20 million for fiscal year 2025.
- Design Therapeutics, Inc. showed a decrease of -10.3% in Total Assets compared to the prior fiscal year.
- Design Therapeutics, Inc. reported Cash and Equivalents of $16.86 million for fiscal year 2025.
- Design Therapeutics, Inc. showed a decrease of -25.3% in Cash and Equivalents compared to the prior fiscal year.
- Design Therapeutics, Inc. reported Stockholders Equity of $212.50 million for fiscal year 2025.
- Design Therapeutics, Inc. showed a decrease of -12.2% in Stockholders Equity compared to the prior fiscal year.
- Design Therapeutics, Inc. reported R&D Expense of $59.13 million for fiscal year 2025.
- Design Therapeutics, Inc. showed an increase of +33.3% in R&D Expense compared to the prior fiscal year.
- Design Therapeutics, Inc. reported Operating Income of -$79.47 million for fiscal year 2025.
- Design Therapeutics, Inc. showed a decrease of -27.4% in Operating Income compared to the prior fiscal year.
- Design Therapeutics, Inc. reported Shares Outstanding of 60.40 million shares for fiscal year 2025.
- Design Therapeutics, Inc. showed an increase of +6.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: